Imai H, Nakano Y, Kiyosawa K, Tan E M
W. M. Keck Autoimmune Disease Center, Scripps Research Institute, La Jolla, CA 92037.
Cancer. 1993 Jan 1;71(1):26-35. doi: 10.1002/1097-0142(19930101)71:1<26::aid-cncr2820710106>3.0.co;2-n.
Patients with liver cirrhosis and chronic hepatitis are at high risk for development of hepatocellular carcinoma (HCC). In HCC and other malignant neoplasms, antinuclear antibodies (ANA) have been detected, but the clinical and biologic significance of these autoantibodies has not been established. This study documents changing ANA manifested as seroconversion from a negative to positive ANA status, increasing titers, and changing antibody specificities in patients in whom chronic liver disease has progressed to HCC.
Sera were collected from patients with chronic liver diseases and HCC in Japan. Indirect immunofluorescence was used to detect ANA, and Western blotting, two-dimensional immunoblotting, and enzyme-linked immunosorbent assay were used to characterize nuclear antigen-antibody systems.
ANA were detected in 57 of 183 (31%) patients with HCC, a statistically higher frequency than in patients with the most common antecedent clinical conditions, liver cirrhosis (9 of 64 patients [14%]; P < 0.05) or chronic hepatitis (16 of 123 patients [13%]; P < 0.001). One patient with autoimmune hepatitis observed for 9 years had a decrease in ANA titer after therapy with corticosteroid and azathioprine and had a rebound increase in ANA titer associated with development of HCC. Immunologic assays demonstrated dramatic decreases in levels of autoantibodies to histones during therapy and the appearance of new autoantibodies coincident with HCC. Changes in ANA associated with the appearance of auto-antibodies of new specificities were documented in four other patients with chronic liver disease in whom HCC developed.
Changes in ANA, especially alterations in autoantibody specificities, are seen infrequently in systemic autoimmune diseases. It is possible that in HCC such changes in ANA might reflect autoimmune responses to intranuclear antigens that are perturbed in cellular transformation.
肝硬化和慢性肝炎患者发生肝细胞癌(HCC)的风险很高。在HCC和其他恶性肿瘤中已检测到抗核抗体(ANA),但这些自身抗体的临床和生物学意义尚未明确。本研究记录了慢性肝病进展为HCC的患者中ANA的变化,表现为ANA状态从阴性转为阳性、滴度升高以及抗体特异性改变。
收集日本慢性肝病和HCC患者的血清。采用间接免疫荧光法检测ANA,采用蛋白质印迹法、二维免疫印迹法和酶联免疫吸附测定法对核抗原 - 抗体系统进行特征分析。
183例HCC患者中有57例(31%)检测到ANA,其发生率在统计学上高于最常见的前驱临床疾病患者,即肝硬化患者(64例患者中有9例[14%];P < 0.05)或慢性肝炎患者(123例患者中有16例[13%];P < 0.001)。1例观察9年的自身免疫性肝炎患者在接受皮质类固醇和硫唑嘌呤治疗后ANA滴度下降,而在发生HCC时ANA滴度出现反弹升高。免疫测定显示治疗期间针对组蛋白的自身抗体水平显著下降,且出现了与HCC同时发生的新自身抗体。在另外4例发生HCC的慢性肝病患者中也记录到了与新特异性自身抗体出现相关的ANA变化。
ANA的变化,尤其是自身抗体特异性的改变,在系统性自身免疫性疾病中很少见。在HCC中,这种ANA变化可能反映了对细胞转化过程中受到干扰的核内抗原的自身免疫反应。